<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Dihydroergotamine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00320</strong>&#160; (APRD00476)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A 9,10alpha-dihydro derivative of ergotamine. It is used as a vasoconstrictor, specifically for the therapy of migraine disorders. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00320/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00320/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00320.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00320.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00320.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00320.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00320.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00320">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IUPAC</td></tr><tr><td>9,10-dihydroergotamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dihidroergotamina</td><td>Spanish</td><td>INN</td></tr><tr><td>Dihydroergotamin</td><td>German</td><td>INN</td></tr><tr><td>Dihydroergotamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>BAN, DCF</td></tr><tr><td>Dihydroergotaminum</td><td>Latin</td><td>INN</td></tr><tr><td>Diidroergotamina</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCIT</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Dihydroergotamine Mesylate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000997/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000997/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000997">DBSALT000997</a></td>
      </tr>
      <tr>
        <td>
          <strong>Dihydroergotamine Tartrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001066/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001066/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001066">DBSALT001066</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>D.H.E. 45</td><td>Valeant</td></tr><tr><td>Dihydergot</td><td>Sandoz</td></tr><tr><td>Ergont</td><td>Sigmapharm</td></tr><tr><td>Ergotonin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ikaran</td><td>Pierre Fabre</td></tr><tr><td>Migranal</td><td>Valeant</td></tr><tr><td>Orstanorm</td><td>Amdipharm</td></tr><tr><td>Verladyn</td><td>Verla</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/vasoconstrictor-agents">Vasoconstrictor Agents</a></li>
<li><a href="/mesh/dopamine-agonists">Dopamine Agonists</a></li>
<li><a href="/mesh/analgesics-non-narcotic">Analgesics, Non-Narcotic</a></li>
<li><a href="/mesh/anti-migraine-agents">Anti-migraine Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>6190-39-2</td></tr><tr><th>Weight</th><td>Average: 583.6774<br>Monoisotopic: 583.279469319</td></tr><tr><th>Chemical Formula</th><td>C<sub>33</sub>H<sub>37</sub>N<sub>5</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>LUZRJRNZXALNLM-JGRZULCMSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00320.gif?1265922771">show</a>(10.9 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Ergolines and Derivatives</td></tr><tr><th>Subclass</th><td>Lysergic Acids and Derivatives</td></tr><tr><th>Direct parent</th><td>Ergotamines, Dihydroergotamines, and Derivatives</td></tr><tr><th>Alternative parents</th><td>Cyclic Peptides; Clavines and Derivatives; Indoloquinolines; Benzoquinolines; N-acyl-alpha Amino Acids and Derivatives; Pyrroloquinolines; Quinoline Carboxamides; N-substituted Nicotinamides; Indoles; Piperidinecarboxylic Acids; Isoindoles and Derivatives; Oxazolidinediones; Benzene and Substituted Derivatives; Piperazines; Diazinanes; Pyrroles; Pyrrolidines; Tertiary Carboxylic Acid Amides; Secondary Carboxylic Acid Amides; Tertiary Amines; Enolates; Polyamines; Carboxylic Acids; Ethers; Ergoline Derivatives</td></tr><tr><th>Substituents</th><td>cyclic alpha peptide; clavine skeleton; ergoline skeleton; indoloquinoline; benzoquinoline; pyrroloquinoline; quinoline-3-carboxamide; n-acyl-alpha amino acid or derivative; quinoline; n-substituted nicotinamide; indole or derivative; isoindole or derivative; indole; piperidinecarboxylic acid; oxazolidinedione; piperazine; 1,4-diazinane; piperidine; benzene; pyrrole; tertiary carboxylic acid amide; pyrrolidine; carboxamide group; tertiary amine; secondary carboxylic acid amide; ether; polyamine; carboxylic acid derivative; carboxylic acid; enolate; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the ergotamines, dihydroergotamines, and derivatives. These are organic compounds containing an ergotamine moiety, which is structurally characterized by a benzyl substituent attached to the piperazine ring of the ergopeptine backbone.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.</td></tr><tr><th>Pharmacodynamics</th><td>Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT<sub>1D</sub>a and 5-HT<sub>1D</sub>b receptors. It also binds with high affinity to serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>2C</sub> receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT<sub>1D</sub> receptors.</td></tr><tr><th>Mechanism of action</th><td>Two theories have been proposed to explain the efficacy of 5-HT<sub>1D</sub> receptor agonists in migraine: 1) activation of 5-HT<sub>1D</sub> receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache and 2) activation of 5-HT<sub>1D</sub> receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.</td></tr><tr><th>Absorption</th><td>Interpatient variable and may be dependent on the administration technique</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>800 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>93% (to plasma proteins)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td>The major excretory route of dihydroergotamine is via the bile in the feces. 
Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection.</td></tr><tr><th>Half life</th><td>9 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>1.5 L/min</li>
</ul></td></tr><tr><th>Toxicity</th><td>Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8348</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9817</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7956</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8223</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.556</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8388</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8229</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7897</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7227</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.895</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.712</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.591</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.897
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9549
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9961
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9503 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9365
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5788
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Valeant pharmaceuticals international</li>
<li>Bedford laboratories</li>
<li>Paddock laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.draxispharma.com">Draxis Specialty Pharmaceuticals Inc.</a></li>
<li><a href="http://www.mipharm.it">Mipharm S.P.A.</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.paddocklabs.com">Paddock Labs</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Liquid</td><td>Nasal</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>D.H.E. 45 1 mg/ml Solution 1ml Ampule</td><td>124.61USD</td><td>ampule</td></tr><tr><td>D.H.E. 45 1 mg/ml ampul</td><td>120.88USD</td><td>ml</td></tr><tr><td>Migranal 4 mg/ml Solution 1ml Glass Container</td><td>94.46USD</td><td>container</td></tr><tr><td>Migranal nasal spray</td><td>90.83USD</td><td>ml</td></tr><tr><td>D.h.e.45 1 mg/ml ampul</td><td>54.46USD</td><td>ml</td></tr><tr><td>Dihydroergotamine 1 mg/ml am</td><td>38.0USD</td><td>ml</td></tr><tr><td>Dihydroergotamine Mesylate 1 mg/ml Solution 1ml Ampule</td><td>36.4USD</td><td>ampule</td></tr><tr><td>Migranal 4 mg/ml Spray</td><td>11.17USD</td><td>spray</td></tr><tr><td>Dihydroergotamine (Dhe) 1 mg/ml</td><td>4.18USD</td><td>ml</td></tr><tr><td>Dihydroergotamine Mesylate 1 mg/ml</td><td>3.9USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5169849</td><td>1992-12-08</td><td>2009-12-08</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>logP</td><td>2</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>2.29e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.04</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.71</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.4</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>9.71</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>8.39</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>118.21</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>159.39</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>63.3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07798" target="_blank">C07798 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10531" target="_blank">10531 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507711" target="_blank">46507711 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.10091.html" target="_blank">10091 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=4562" target="_blank">4562 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1732" target="_blank">CHEMBL1732 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000078" target="_blank">DAP000078 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164743028" target="_blank">PA164743028 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2241163" target="_blank">2241163 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/dihyergmes.htm" target="_blank">http://www.rxlist.com/cgi/generic2/dihyergmes.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/dihydroergotamine.html" target="_blank">http://www.drugs.com/cdi/dihydroergotamine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mig1267.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mig1267.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Dihydroergotamine" target="_blank">Dihydroergotamine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N02CA01<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N02#N02">N02 &#8212; ANALGESICS</a></li><li><a href="/atc/N02C#N02C">N02C &#8212; ANTIMIGRAINE PREPARATIONS</a></li><li><a href="/atc/N02CA#N02CA">N02CA &#8212; Ergot alkaloids</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>12:16.00</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00320.pdf?1265922798">show</a>(412 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00320.pdf?1265922738">show</a>(53.1 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01612">Amyl Nitrite</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase the therapeutic and adverse effects of dihydroergotamine.</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Risk of ergotism and severe ischemia with this association</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dihydroergotamine if delavirdine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Efavirenze may increase the adverse/toxic effects of dihydroergotamine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01613">Erythrityl Tetranitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Amprenavir increases the effect and toxicity of ergot derivative</td></tr><tr><td><a href="/drugs/DB00998">Frovatriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00883">Isosorbide Dinitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01020">Isosorbide Mononitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Ischemia with risk of gangrene.</td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>Naratriptan, a serotonin 5-HT1D receptor agonists, may increase the vasoconstricting effect of dihydroergotamine. Concomitant use of these two agents within 24 hours is contraindicated.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir increases the effect and toxicity of ergot derivative</td></tr><tr><td><a href="/drugs/DB00727">Nitroglycerin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB06154">Pentaerythritol Tetranitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Contraindicated co-administration</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine.</td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine.</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Dihydroergotamine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Dihydroergotamine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB01361">Troleandomycin</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00744">Zileuton</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, dihydroergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>